MIT Technology Review hosted a subscriber discussion examining longevity's shift toward cellular reprogramming, where scientists aim to reset cells to younger states. The session featured science editor Mary Beth Griggs and senior biotechnology reporter Jessica Hamzelou exploring whether experimental anti-aging treatments can deliver on their promises.

The conversation addressed the massive influx of capital into longevity research, with billions of dollars flowing toward reversing aging processes. While the approach shows scientific promise, researchers face significant hurdles in translating cellular reprogramming from lab experiments to viable human treatments.

Several companies now pursue various strategies to restore cellular youth, though most remain in early-stage development. The discussion highlighted both the excitement around potential breakthroughs and the realistic timeline challenges that could delay widespread applications for decades.

Despite the hype, fundamental questions about efficacy, safety, and accessibility remain unanswered. These experimental approaches may revolutionize medicine, but they're still far from proven therapies that can reliably extend healthy human lifespan.